NCT01852591 · OUTCOME

CD8+CD107a+, Best Response Against Vaccine (CRM 197)

Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant · Source last updated 2017-02-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of CD8 cells
Interval / dispersion: Not reported
Time frame: 30 Days Post Vaccine

What was measured

Best CD8+ response against CRM197 at day +30 for CD107a. Peripheral Blood Mononuclear Cells (PBMCs) were incubated with CRM197, or control. Cells were harvested and stained for flow cytometry.

Analysis population: All evaluable participants.

Groups in this outcome

Experimental: PCV 13

Pneumococcal conjugate vaccine (PCV 13), 0.5ml, 3 to 30 days prior to transplant and then again at 7-10 and 21-24 days after transplant.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Experimental: PCV 13	5

Reported measurements

Highest % of CD8 cells Pre-vaccine

Values in percentage of CD8 cells · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Experimental: PCV 13	1.19	Not reported	Not reported	Not reported	Not reported

Best Response % of CD8 cells Day +30

Values in percentage of CD8 cells · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Experimental: PCV 13	8.94	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
1.19
title
Highest % of CD8 cells Pre-vaccine
categories
measurements
group Id
OG000
value
8.94
title
Best Response % of CD8 cells Day +30

denoms

counts
group Id
OG000
value
5
units
Participants

description

Best CD8+ response against CRM197 at day +30 for CD107a. Peripheral Blood Mononuclear Cells (PBMCs) were incubated with CRM197, or control. Cells were harvested and stained for flow cytometry.

groups

description
Pneumococcal conjugate vaccine (PCV 13), 0.5ml, 3 to 30 days prior to transplant and then again at 7-10 and 21-24 days after transplant.
id
OG000
title
Experimental: PCV 13

param Type

NUMBER

population Description

All evaluable participants.

reporting Status

POSTED

time Frame

30 Days Post Vaccine

title

CD8+CD107a+, Best Response Against Vaccine (CRM 197)

type

SECONDARY

unit Of Measure

percentage of CD8 cells

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice